title: Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State.
abstract: Although the existence of an immune response against tumor cells is well documented, the fact that tumors take off in cancer patients indicates that neoplastic cells can circumvent this response. Over the years many investigators have described strategies to rescue the anti-tumor immune response with the aim of creating specific and long-lasting protection against the disease. When exported to human clinical settings, these strategies have revealed in most cases a very limited, if any, positive outcome. We believe that the failure is mostly due to the inadequate triggering of the CD4+ T helper (TH) cell arm of the adaptive immunity, as TH cells are necessary to trigger all the immune effector mechanisms required to eliminate tumor cells. In this review, we focus on novel strategies that by stimulating MHC class II-restricted activation of TH cells generate a specific and persistent adaptive immunity against the tumor. This point is of critical importance for both preventive and therapeutic anti-tumor vaccination protocols, because adaptive immunity with its capacity to produce specific, long-lasting protection and memory responses is indeed the final goal of vaccination. We will discuss data from our as well as other laboratories which strongly suggest that triggering a specific and persistent anti-tumor CD4+ TH cell response stably modify not only the tumor microenvironment but also tumor-dependent extratumor microenvironments by eliminating and/or reducing the blood-derived tumor infiltrating cells that may have a pro-tumor growth function such as regulatory CD4+/CD25+ T cells and myeloid-derived-suppressor cells. Within this frame, therefore, we believe that the establishment of a pro-tumor environment is not the cause but simply the consequence of the tumor strategy to primarily counteract components of the adaptive cellular immunity, particularly TH lymphocytes.
authors.affiliation: Department of Surgical and Morphological Sciences, University of Insubria , Varese , Italy.
authors.forename: Roberto S
authors.initials: RS
authors.lastname: Accolla
authors.affiliation: Department of Surgical and Morphological Sciences, University of Insubria , Varese , Italy.
authors.forename: Letizia
authors.initials: L
authors.lastname: Lombardo
authors.affiliation: Department of Surgical and Morphological Sciences, University of Insubria , Varese , Italy.
authors.forename: Rawan
authors.initials: R
authors.lastname: Abdallah
authors.affiliation: Department of Surgical and Morphological Sciences, University of Insubria , Varese , Italy.
authors.forename: Goutham
authors.initials: G
authors.lastname: Raval
authors.affiliation: Department of Surgical and Morphological Sciences, University of Insubria , Varese , Italy.
authors.forename: Greta
authors.initials: G
authors.lastname: Forlani
authors.affiliation: Department of Surgical and Morphological Sciences, University of Insubria , Varese , Italy.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Tosi
keywords: CIITA; MHC class II; T helper cells; anti-tumor immunity; tumor vaccines